Now, the new FDA approval means that patients will be able use the ketamine-derived nasal spray, which is marketed under the brand name Spravato, without having to be on another type of ...

The remaining 20% is their coinsurance. S-ketamine, or esketamine (Spravato), is an FDA-approved nasal spray that doctors and healthcare professionals may prescribe for major depressive disorder ...

The 2019 winner of "RuPaul's Drag Race UK," who died in January, had experienced cardiac arrest following ketamine use, The ...

making the nasal spray the only authorized standalone therapy for treatment-resistant depression. According to Reilly, IV and intramuscular ketamine have not received FDA approval because they ...

In 2019, esketamine (Spravato), derived from ketamine, was approved by the FDA as a nasal spray for treatment-resistant depression. While ketamine therapy has shown promising results, its use ...

S-ketamine, also called esketamine (Spravato), is a nasal spray with FDA approval for treatment-resistant depression and major depressive disorder with suicidal ideation. Esketamine (Spravato ...